• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aerie resubmits NDA for Rhopressa eye drops

March 1, 2017 By Sarah Faulkner

Aerie resubmits NDA for Rhopressa eye dropsAerie Pharmaceuticals (NSDQ:AERI) said today that it resubmit a New Drug Application for the company’s Rhopressa eye drops. The Irvine, Calif.-based company’s NDA was withdrawn in October last year, after a contract manufacturer was not prepared for its pre-approval inspection.

Aerie’s Rhopressa eye drops specifically target the eye’s trabecular network – the diseased tissue responsible for elevated intraocular pressure in patients with glaucoma.

The company said that if the eye drops are approved, the product would be the only once-daily therapy to target the trabecular network.

“We are delighted to have our Rhopressa NDA filing back on track, and we expect a standard 12-month FDA review process from the date of resubmission. Pending approval, we anticipate product launch in the second quarter of 2018,” chairman & CEO Vicente Anido, Jr. said in prepared remarks. “Looking forward to additional upcoming milestones, we continue to expect in the 2nd quarter of 2017, the readout of the six-month safety and efficacy data for the Rhopressa Phase III registration trial, known as Rocket 4. We also anticipate in the 2nd quarter of 2017, the readout of the 90-day efficacy data from Mercury 2, our 2nd Phase III registration trial for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%.”

In December, Aerie said that it completed enrollment for its 2nd phase III registration trial, Mercury 2, evaluating its Roclatan once-daily eye drops for intraocular pressure resulting from glaucoma or ocular hypertension.

The company’s Roclatan solution is a fixed dose combination of its drug Rhopressa (netarsudil ophthalmic solution) and latanoprost, a widely prescribed prostaglandin analogue. More than 690 patients are enrolled in the 3-arm study, comparing the Roclatan solution to each of its individual components.

In September, the company touted successful topline efficacy results from its 1st phase III registration trial, Mercury 1, for Roclatan.

The trial achieved its primary efficacy endpoint, demonstrating superiority over its components. Aerie said it will launch a 3rd phase III registration trial for Roclatan in the 1st half of 2017, which will be designed to support regulatory approval and commercialization efforts in Europe.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance, Wall Street Beat Tagged With: Aerie Pharmaceuticals

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Reader Interactions

Comments

  1. Mary accaputo says

    December 24, 2018 at 1:21 pm

    my doctor prescribed rhopressa for my eye, but I cannot afford this medicine. I have Aetna for my drug medicine and it cost $286. can you tell me where or how I can purchase this drug at a lower cost?

  2. Claude A Shaffer says

    February 1, 2019 at 11:23 am

    My question is exactly the sams as Mary.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS